BHCM
VTVT icon

Brevan Howard Capital Management’s vTv Therapeutics VTVT Stock Holding History

Brevan Howard Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,531
Closed -$299K – 2624
2026
Q1 		$299K Buy
+7,531
New +$273K ﹤0.01% 1623

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's VTVT Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of vTv Therapeutics (VTVT) in Q2 2026, closing a stake of 7,531 shares — an estimated $299K sold.

Brevan Howard Capital Management first reported a position in VTVT in Q1 2026 and held it in 1 quarter. The position peaked at $299K in Q1 2026. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining vTv Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 7,531 vTv Therapeutics shares in Q2 2026, an estimated $299K.
  • Brevan Howard Capital Management first reported a position in vTv Therapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's vTv Therapeutics position peaked at $299K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.